Receptors, Progesterone

• 

  Subject Areas on Research

  • 16 alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. 
  • A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. 
  • A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features. 
  • A membrane-associated progesterone-binding protein, 25-Dx, is regulated by progesterone in brain regions involved in female reproductive behaviors. 
  • A novel, highly regulated, rapidly inducible system for the expression of chicken progesterone receptor, cPRA, in Saccharomyces cerevisiae. 
  • A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. 
  • A truncated progesterone receptor (PR-M) localizes to the mitochondrion and controls cellular respiration. 
  • A-ring reduced metabolites of 19-nor synthetic progestins as subtype selective agonists for ER alpha. 
  • Absence of mitochondrial progesterone receptor polymorphisms in women with spontaneous preterm birth. 
  • Abundance and Localization of Progesterone Receptor Isoforms in Endometrium in Women With and Without Endometriosis and in Peritoneal and Ovarian Endometriotic Implants. 
  • Actions of steroids in mitochondria. 
  • Additive estrogenic activities of a binary mixture of 2',4',6'-trichloro- and 2',3',4',5'-tetrachloro-4-biphenylol. 
  • Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data. 
  • Aggressive fibromatosis. 
  • Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated BV-2 microglia. 
  • Are all aromatase inhibitors alike? 
  • Association of aspirin use and hormone receptor status with breast cancer risk. 
  • Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. 
  • BMI influences prognosis following surgery and adjuvant chemotherapy for lymph node positive breast cancer. 
  • Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. 
  • Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol. 
  • Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. 
  • Breast cancer survival in African-American women by hormone receptor subtypes. 
  • Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. 
  • CDB-4124 does not cause apoptosis in cultured fibroid cells. 
  • Characterization of progesterone receptor isoform expression in fetal membranes. 
  • Chicken progesterone receptor expressed in Saccharomyces cerevisiae is correctly phosphorylated at all four Ser-Pro phosphorylation sites. 
  • Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care. 
  • Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors. 
  • Cloning and expression of a novel, truncated, progesterone receptor. 
  • Connections and regulation of the human estrogen receptor. 
  • Creatine kinase activity as an indicator of unopposed estrogen action in the mouse uterus associated with anti-progesterone treatment. 
  • Cystosarcoma phylloides. A steroid receptor and ultrastructure analysis. 
  • Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors. 
  • Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor. 
  • Development of the human female reproductive tract. 
  • Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer. 
  • Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin. 
  • Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. 
  • Effects of an oral contraceptive combination with or without androgen on mammary tissues: a study in rats. 
  • Effects of genistein or soy milk during late gestation and lactation on adult uterine organization in the rat. 
  • Endocrine therapy in metastatic breast cancer. 
  • Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). 
  • Endometrial receptivities after leuprolide suppression and gonadotropin stimulation: histology, steroid receptor concentrations, and implantation rates. 
  • Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. 
  • Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. 
  • Expression of a mitochondrial progesterone receptor (PR-M) in leiomyomata and association with increased mitochondrial membrane potential. 
  • Expression of a mitochondrial progesterone receptor in human spermatozoa correlates with a progestin-dependent increase in mitochondrial membrane potential. 
  • Expression of functional chicken oviduct progesterone receptors in yeast (Saccharomyces cerevisiae). 
  • Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. 
  • Frequency of breast cancer subtypes among African American women in the AMBER consortium. 
  • Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer. 
  • Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. 
  • Heterogeneity in the hormonal responsiveness of clones derived from the 13762NF rat mammary tumor. 
  • High inhibitory activity of a new antiestrogen, RU 16117 (11alpha-methoxy ethinyl estradiol), on the development of dimethylbenz(a)anthracene-induced mammary tumors. 
  • High level expression of a truncated chicken progesterone receptor in Escherichia coli. 
  • High throughput, cell type-specific analysis of key proteins in human endometrial biopsies of women from fertile and infertile couples. 
  • Hormone therapy: physiological complexity belies therapeutic simplicity. 
  • Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo. 
  • Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. 
  • Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. 
  • Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. 
  • Identification and characterization of novel estrogen receptor-beta-sparing antiprogestins. 
  • Identification of a negative regulatory function for steroid receptors. 
  • Identification of progesterone receptor in human subcutaneous adipose tissue. 
  • Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. 
  • Immunofluorescent localization of a novel progesterone receptor(s) in a T47D-Y breast cancer cell line lacking genomic progesterone receptor expression. 
  • Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. 
  • Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. 
  • Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. 
  • Interactions of estrogen- and thyroid hormone receptors on a progesterone receptor estrogen response element (ERE) sequence: a comparison with the vitellogenin A2 consensus ERE. 
  • International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. 
  • Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. 
  • Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification. 
  • Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. 
  • Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy? 
  • Jun dimerization protein 2 functions as a progesterone receptor N-terminal domain coactivator. 
  • Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). 
  • Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. 
  • Long-term prognostic implications of sex-steroid receptors in human cancer. 
  • Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. 
  • Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. 
  • Malignant effusions in recurrent breast cancer: steroid hormone receptor analysis of effusion fluid derived cells. 
  • Malignant transformation of the human endometrium is associated with overexpression of lactoferrin messenger RNA and protein. 
  • Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor. 
  • Mechanisms controlling agonist and antagonist potential of selective progesterone receptor modulators (SPRMs). 
  • Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer. 
  • Membrane-bound progesterone receptor expression in human aortic endothelial cells. 
  • Modulation of ATP-induced calcium signaling by progesterone in T47D-Y breast cancer cells. 
  • Modulation of progesterone receptor binding to progesterone response elements by positioned nucleosomes. 
  • Molecular mechanisms of development of the human fetal female reproductive tract. 
  • Multimodal regulation of E2F1 gene expression by progestins. 
  • Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. 
  • Mutant and wild-type androgen receptors exhibit cross-talk on androgen-, glucocorticoid-, and progesterone-mediated transcription. 
  • Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals. 
  • No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. 
  • Novel Hormone Receptors Present in Apocrine Cystadenoma of the Eyelid. 
  • Novel prognostic markers for patients with triple-negative breast cancer. 
  • Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. 
  • Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400. 
  • Pathology and pathophysiology of uterine smooth-muscle tumors. 
  • Performance of preoperative breast MRI based on breast cancer molecular subtype. 
  • Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. 
  • Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. 
  • Phosphorylation of hen progesterone receptor by cAMP dependent protein kinase. 
  • Population and target considerations for triple-negative breast cancer clinical trials. 
  • Potentiation of progesterone receptor-mediated transcription by the immunosuppressant FK506. 
  • Pregnancy and Smoothelin-like Protein 1 (SMTNL1) Deletion Promote the Switching of Skeletal Muscle to a Glycolytic Phenotype in Human and Mice. 
  • Pregnancy without progesterone in horses defines a second endogenous biopotent progesterone receptor agonist, 5α-dihydroprogesterone. 
  • Progesterone inhibits glucocorticoid-induced murine thymocyte apoptosis. 
  • Progesterone receptor activity in leiomyomatosis peritonealis disseminata. 
  • Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. 
  • Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. 
  • Progesterone receptor interacting coregulatory proteins and cross talk with cell signaling pathways. 
  • Progesterone receptor membrane component 1 (PGRMC1) expression in fetal membranes among women with preterm premature rupture of the membranes (PPROM). 
  • Progesterone receptor membrane component 1 as the mediator of the inhibitory effect of progestins on cytokine-induced matrix metalloproteinase 9 activity in vitro. 
  • Progesterone receptor membrane component 1: is metabolism integral to its function and what other steroids are involved? 
  • Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. 
  • Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. 
  • Progesterone receptor-A and -B have opposite effects on proinflammatory gene expression in human myometrial cells: implications for progesterone actions in human pregnancy and parturition. 
  • Progesterone receptors in the human heart and great vessels. 
  • Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells. 
  • Progesterone, Inflammatory Cytokine (TNF-α), and Oxidative Stress (H2O2) Regulate Progesterone Receptor Membrane Component 1 Expression in Fetal Membrane Cells. 
  • Progestins Inhibit Tumor Necrosis Factor α-Induced Matrix Metalloproteinase 9 Activity via the Glucocorticoid Receptor in Primary Amnion Epithelial Cells. 
  • Prostate. III--A structural feature characteristic of the rat prostate 5 alpha-reductase active site. 
  • Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. 
  • RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. 
  • Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. 
  • Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. 
  • Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources. 
  • Regulation of the amino-terminal transcription activation domain of progesterone receptor by a cofactor-induced protein folding mechanism. 
  • Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. 
  • Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. 
  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. 
  • Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. 
  • Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status. 
  • Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. 
  • Roles of Progesterone Receptor Membrane Component 1 in Oxidative Stress-Induced Aging in Chorion Cells. 
  • Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials. 
  • Sex steroid receptor analysis in human melanoma. 
  • Sex steroid receptor concentration in breast carcinoma tissue: effect of devascularization during mastectomy. 
  • Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. 
  • Smoothelin-like 1 protein is a bifunctional regulator of the progesterone receptor during pregnancy. 
  • Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. 
  • Steroids induce hypothalamic progestin receptors and facilitate female sexual behavior in neonatal rats. 
  • Structural organization and regulation of the chicken estrogen receptor. 
  • TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. 
  • The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. 
  • The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. 
  • The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer. 
  • The Novel Progesterone Receptor Antagonists RTI 3021-012 and RTI3021-022 Exhibit Complex Glucocorticoid Receptor Antagonist Activities: Implications for the Development of Dissociated Antiprogestins. 
  • The Role of Progesterone and a Novel Progesterone Receptor, Progesterone Receptor Membrane Component 1, in the Inflammatory Response of Fetal Membranes to Ureaplasma parvum Infection. 
  • The Role of a Mitochondrial Progesterone Receptor (PR-M) in Progesterone Action. 
  • The association between progesterone receptor expression and survival in women with adult granulosa cell tumors. 
  • The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. 
  • The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity. 
  • The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. 
  • The molecular pharmacology of ovarian steroid receptors. 
  • The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? 
  • The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. 
  • The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. 
  • The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. 
  • Tissue interactions and estrogenic response during human female fetal reproductive tract development. 
  • Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. 
  • Type and duration of exogenous hormone use affects breast cancer histology. 
  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. 
  • Validation of a breast cancer risk prediction model developed for Black women. 
  • Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors. 
  • Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. 
  • [Treatment of primary cancer of the breast in elderly women. Role of hormone therapy]. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Halabi, Susan, Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Duke Innovation & Entrepreneurship
  • Moorman, Patricia Gripka, Professor in Family Medicine and Community Health, Duke Cancer Institute